Ketema N. Paul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ketema N. Paul has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- John Christopher Ehlen
Department of Neurobiology, Morehouse School of Medicine, Atlanta, USA
10 shared publications - Christopher S. Colwell
Department of Psychiatry & Biobehavioral Sciences, University of California Los Angeles, Los Angeles, USA
8 shared publications Allison J. Brager
Behavioral Biology Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research
4 shared publications- Cristina Antonella Ghiani
Department of Psychiatry & Biobehavioral Sciences, University of California Los Angeles
4 shared publications Emily Chiem
Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, United States
4 shared publicationsFred W. Turek
B Center for Sleep and Circadian Biology and the Department of Neurobiology and Physiology, Northwestern University, Evanston, IL
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Communications Biology
Daytime illumination shapes sex differences in sleep and circadian responses to nighttime light
Light is the primary environmental cue regulating circadian rhythms and sleep–wake behavior, yet daylight intensity is rarely standardized or reported. This variability may contribute to inconsistent findings on sex differences in sleep regulation. In prior work, we observed no sex differences in sleep–wake architecture under relatively bright daylight, suggesting that daytime illumination may be a critical but underappreciated determinant of sex difference in sleep regulation. Here, we tested whether daylight intensity modulates sex differences in sleep–wake architecture and vulnerability to dim light at night (DLaN). Male and female C57BL/6 J mice were exposed to acute (one night) or chronic (two weeks) DLaN (10-lux) under daytime light intensities of 50-, 100-, or 300-lux. Sleep was assessed using electroencephalographic measures of vigilance states and slow wave activity (SWA). Dim daylight (50-lux) revealed marked sex differences in dark phase that were absent under brighter daylight (300-lux). Acute DLaN reduced early-night wakefulness in both sexes under low daytime light but had little effect under bright daylight conditions. Following chronic DLaN, males showed reduced wakefulness and dampened rhythm amplitude, whereas females exhibited larger phase shifts, rhythm attenuation, and altered SWA timing under 50- and 100-lux, and bright daytime light largely prevented these effects.
- 7 October 2026
- Published by Springer Nature in Communications Biology
Open AccessDaytime illumination shapes sex differences in sleep and circadian responses to nighttime light
Light is the primary environmental cue regulating circadian rhythms and sleep–wake behavior, yet daylight intensity is rarely standardized or reported. This variability may contribute to inconsistent findings on sex differences in sleep regulation. In prior work, we observed no sex differences in sleep–wake architecture under relatively bright daylight, suggesting that daytime illumination may be a critical but underappreciated determinant of sex difference in sleep regulation. Here, we tested whether daylight intensity modulates sex differences in sleep–wake architecture and vulnerability to dim light at night (DLaN). Male and female C57BL/6 J mice were exposed to acute (one night) or chronic (two weeks) DLaN (10-lux) under daytime light intensities of 50-, 100-, or 300-lux. Sleep was assessed using electroencephalographic measures of vigilance states and slow wave activity (SWA). Dim daylight (50-lux) revealed marked sex differences in dark phase that were absent under brighter daylight (300-lux). Acute DLaN reduced early-night wakefulness in both sexes under low daytime light but had little effect under bright daylight conditions. Following chronic DLaN, males showed reduced wakefulness and dampened rhythm amplitude, whereas females exhibited larger phase shifts, rhythm attenuation, and altered SWA timing under 50- and 100-lux, and bright daytime light largely prevented these effects.
- Open Access
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1865440
Sleep and circadian regulation of DNA repair and retrotransposons in neuronal genome stability and neurodegenerative disease mechanisms
Sleep and wake are fundamental brain states that coordinate diverse physiological processes required for long-term health and survival. Recent research in molecular neuroscience and chronobiology has begun to clarify how sleep–wake cycles and circadian timing intersect with genomic maintenance mechanisms in the nervous system. In this Review, we summarize current evidence that sleep and circadian rhythms temporally regulate neuronal genome stability, with a particular focus on how they modulate neuronal retrotransposon activity. We discuss circadian clock-dependent regulation of DNA repair pathways, the contribution of sleep to chromosomal integrity and chromosome dynamics, and emerging data on temporally-dependent retrotransposon activity across the sleep–wake cycle. Taken together, the studies we review suggest that sleep may provide a permissive state during which neurons engage genome-protective processes, including up-regulation of DNA repair factors, changes in chromatin organization, and silencing of retrotransposon activity. We further propose that these mechanisms may be relevant to neurodegenerative disorders, although much of the current evidence linking sleep and circadian disruption to retrotransposon dysregulation, genomic instability, and cognitive decline remains preclinical or correlative in humans.
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1865440
Open AccessSleep and circadian regulation of DNA repair and retrotransposons in neuronal genome stability and neurodegenerative disease mechanisms
Sleep and wake are fundamental brain states that coordinate diverse physiological processes required for long-term health and survival. Recent research in molecular neuroscience and chronobiology has begun to clarify how sleep–wake cycles and circadian timing intersect with genomic maintenance mechanisms in the nervous system. In this Review, we summarize current evidence that sleep and circadian rhythms temporally regulate neuronal genome stability, with a particular focus on how they modulate neuronal retrotransposon activity. We discuss circadian clock-dependent regulation of DNA repair pathways, the contribution of sleep to chromosomal integrity and chromosome dynamics, and emerging data on temporally-dependent retrotransposon activity across the sleep–wake cycle. Taken together, the studies we review suggest that sleep may provide a permissive state during which neurons engage genome-protective processes, including up-regulation of DNA repair factors, changes in chromatin organization, and silencing of retrotransposon activity. We further propose that these mechanisms may be relevant to neurodegenerative disorders, although much of the current evidence linking sleep and circadian disruption to retrotransposon dysregulation, genomic instability, and cognitive decline remains preclinical or correlative in humans.
- Open Access
Bright Days Buffer Nighttime Light: Daytime Illumination Shapes Sex Differences in Sleep and Circadian Regulation
Summary: Sex differences in sleep and wakefulness are well documented in humans but remain inconsistent in rodent studies, suggesting strong sensitivity to experimental context. In prior work, we observed no sex differences in sleep-wake architecture under relatively bright daytime light, raising the possibility that daytime illumination is a critical but underappreciated variable shaping sex-dependent sleep regulation. Here, we tested the hypothesis that daytime light intensity modulates sex differences in sleep-wake architecture and vulnerability to dim light at night (DLaN). Male and female C57BL/6J mice were exposed to acute (one night) or chronic (two weeks) DLaN (10 lux) under three daytime light intensities (50, 100, 300 lux). Sleep was assessed using electroencephalographic-based measures of vigilance states and slow wave activity (SWA). Dim daytime light (50 lux) unmasked robust sex differences in dark-phase sleep-wake architecture that were absent under brighter daytime light (300 lux). Acute DLaN reduced early-night wakefulness in both sexes under low daytime light but had minimal effect under bright daytime conditions. Following chronic DLaN, males exhibited reduced dim light-phase wakefulness and dampened rhythm amplitude, whereas females showed pronounced phase shifts, rhythm attenuation, and altered timing of SWA under 50 and 100 lux. These changes were largely prevented under bright daytime light. Together, these findings identify daytime light intensity as a critical contextual factor governing sex-specific regulation of sleep and vulnerability to nighttime light, providing a unifying framework to reconcile inconsistencies in the rodent sleep literature. Highlights: Daytime light intensity shapes sex differences in sleep–wake architecture Acute and chronic nighttime light elicit distinct sex-specific sleep responses Females exhibit greater circadian and slow-wave vulnerability to nighttime light Brighter daytime light buffers sleep and circadian disruption
Open AccessBright Days Buffer Nighttime Light: Daytime Illumination Shapes Sex Differences in Sleep and Circadian Regulation
Summary: Sex differences in sleep and wakefulness are well documented in humans but remain inconsistent in rodent studies, suggesting strong sensitivity to experimental context. In prior work, we observed no sex differences in sleep-wake architecture under relatively bright daytime light, raising the possibility that daytime illumination is a critical but underappreciated variable shaping sex-dependent sleep regulation. Here, we tested the hypothesis that daytime light intensity modulates sex differences in sleep-wake architecture and vulnerability to dim light at night (DLaN). Male and female C57BL/6J mice were exposed to acute (one night) or chronic (two weeks) DLaN (10 lux) under three daytime light intensities (50, 100, 300 lux). Sleep was assessed using electroencephalographic-based measures of vigilance states and slow wave activity (SWA). Dim daytime light (50 lux) unmasked robust sex differences in dark-phase sleep-wake architecture that were absent under brighter daytime light (300 lux). Acute DLaN reduced early-night wakefulness in both sexes under low daytime light but had minimal effect under bright daytime conditions. Following chronic DLaN, males exhibited reduced dim light-phase wakefulness and dampened rhythm amplitude, whereas females showed pronounced phase shifts, rhythm attenuation, and altered timing of SWA under 50 and 100 lux. These changes were largely prevented under bright daytime light. Together, these findings identify daytime light intensity as a critical contextual factor governing sex-specific regulation of sleep and vulnerability to nighttime light, providing a unifying framework to reconcile inconsistencies in the rodent sleep literature. Highlights: Daytime light intensity shapes sex differences in sleep–wake architecture Acute and chronic nighttime light elicit distinct sex-specific sleep responses Females exhibit greater circadian and slow-wave vulnerability to nighttime light Brighter daytime light buffers sleep and circadian disruption
- Open Access
- 18 December 2025
- Published by Springer Nature in Molecular Autism
- Vol. 16 (1) , 62
Dim light at night disrupts the sleep-wake cycle and exacerbates abnormal EEG activity in Cntnap2 knockout mice: implications for autism spectrum disorders
Background: Epilepsy is a common comorbidity in individuals with autism spectrum disorders (ASDs). Many patients with epilepsy as well as ASD experience disruptions in their sleep-wake cycle and daily fluctuations in symptom severity. Chronic exposure to light at nighttime can disrupt sleep and circadian rhythms. Contactin associated protein-like 2 knockout ( Cntnap2 KO) mice, a model of ASD and epilepsy, exhibit sleep and circadian disturbances and abnormal events in the electroencephalogram (EEG). Here, we investigated how chronic dim light at night (DLaN) exposure affects sleep architecture, EEG power spectra, and abnormal EEG events in Cntnap2 KO and wildtype (WT) mice. Methods: Male and female Cntnap2 KO and WT mice were exposed to DLaN (5 lx) for 6 weeks. EEG recordings were collected and analyzed to assess sleep architecture, spectral power, and abnormal EEG events. A two-way repeated-measures analysis of variance (ANOVA) was used to evaluate the effects of DLaN across time and EEG frequencies, followed by Bonferroni-corrected post hoc tests where appropriate. Results: DLaN exposure delayed wake onset and disrupted sleep patterns in a sex-dependent manner, with females being more affected. DLaN significantly increased slow-wave activity (SWA, 0.5–4 Hz) in both WT and KO mice, consistent with increased sleep pressure. Notably, DLaN markedly elevated the frequency of abnormal hypersynchronized EEG events in Cntnap2 KO mice and even induced such events in WT mice. Spectral analysis of abnormal EEG events revealed elevated theta power, suggesting hippocampal involvement. Conclusions: Chronic DLaN exposure disrupts sleep architecture in a sex-dependent fashion and increases the occurrence of abnormal EEG events in Cntnap2 KO mice. These findings highlight the potential risks of nighttime light exposure for individuals with ASD and epilepsy, underscoring the importance of managing light environments to improve sleep quality and neurological health.
- 18 December 2025
- Published by Springer Nature in Molecular Autism
- Vol. 16 (1) , 62
Open AccessDim light at night disrupts the sleep-wake cycle and exacerbates abnormal EEG activity in Cntnap2 knockout mice: implications for autism spectrum disorders
Background: Epilepsy is a common comorbidity in individuals with autism spectrum disorders (ASDs). Many patients with epilepsy as well as ASD experience disruptions in their sleep-wake cycle and daily fluctuations in symptom severity. Chronic exposure to light at nighttime can disrupt sleep and circadian rhythms. Contactin associated protein-like 2 knockout ( Cntnap2 KO) mice, a model of ASD and epilepsy, exhibit sleep and circadian disturbances and abnormal events in the electroencephalogram (EEG). Here, we investigated how chronic dim light at night (DLaN) exposure affects sleep architecture, EEG power spectra, and abnormal EEG events in Cntnap2 KO and wildtype (WT) mice. Methods: Male and female Cntnap2 KO and WT mice were exposed to DLaN (5 lx) for 6 weeks. EEG recordings were collected and analyzed to assess sleep architecture, spectral power, and abnormal EEG events. A two-way repeated-measures analysis of variance (ANOVA) was used to evaluate the effects of DLaN across time and EEG frequencies, followed by Bonferroni-corrected post hoc tests where appropriate. Results: DLaN exposure delayed wake onset and disrupted sleep patterns in a sex-dependent manner, with females being more affected. DLaN significantly increased slow-wave activity (SWA, 0.5–4 Hz) in both WT and KO mice, consistent with increased sleep pressure. Notably, DLaN markedly elevated the frequency of abnormal hypersynchronized EEG events in Cntnap2 KO mice and even induced such events in WT mice. Spectral analysis of abnormal EEG events revealed elevated theta power, suggesting hippocampal involvement. Conclusions: Chronic DLaN exposure disrupts sleep architecture in a sex-dependent fashion and increases the occurrence of abnormal EEG events in Cntnap2 KO mice. These findings highlight the potential risks of nighttime light exposure for individuals with ASD and epilepsy, underscoring the importance of managing light environments to improve sleep quality and neurological health.
- Open Access
Dim Light at Night Disrupts the Sleep-Wake Cycle and Exacerbates Seizure Activity in Cntnap2 Knockout Mice: Implications for Autism Spectrum Disorders
Epilepsy is one of the most common comorbidities in individuals with autism spectrum disorders (ASDs). Many patients with epilepsy as well as ASD experience disruptions in their sleep-wake cycle and exhibit daily rhythms in expression of symptoms. Chronic exposure to light at nighttime can disrupt sleep and circadian rhythms. Contactin associated protein-like 2 knockout ( Cntnap2 KO) mice, a model for autism spectrum disorder (ASD) and epilepsy, exhibit sleep and circadian disturbances and seizure-like events. This study examines how chronic dim light at night (DLaN) exposure affects sleep architecture, EEG power spectra, and seizure activity in Cntnap2 KO and wildtype (WT) mice. Using electroencephalography (EEG) recordings, male and female Cntnap2 KO and WT mice were exposed to DLaN (5 lux) for 2 or 6 weeks. EEG recordings were analyzed to assess sleep architecture, power spectrum, and seizure-like events. DLaN exposure delays the wake onset and disrupts sleep patterns in a sex-dependent manner, with females being more affected. DLaN significantly increased slow-wave activity (SWA, 0.5–4 Hz) in both WT and KO mice, indicating increased sleep pressure. Finally, we found that DLaN dramatically increased the frequency of seizure-like events in the Cntnap2 KO mice and even increased the occurrence rate in the WT mice. Spectral analysis of seizure-like events revealed increased theta power, suggesting the involvement of hippocampus. Chronic DLaN exposure disrupts sleep and increases seizure-like events in Cntnap2 KO mice, with sex-specific differences. These findings emphasize the potential risks of nighttime light exposure for individuals with ASD and epilepsy, reinforcing the need to manage light exposure to improve sleep quality and reduce seizure risk.
Open AccessDim Light at Night Disrupts the Sleep-Wake Cycle and Exacerbates Seizure Activity in Cntnap2 Knockout Mice: Implications for Autism Spectrum Disorders
Epilepsy is one of the most common comorbidities in individuals with autism spectrum disorders (ASDs). Many patients with epilepsy as well as ASD experience disruptions in their sleep-wake cycle and exhibit daily rhythms in expression of symptoms. Chronic exposure to light at nighttime can disrupt sleep and circadian rhythms. Contactin associated protein-like 2 knockout ( Cntnap2 KO) mice, a model for autism spectrum disorder (ASD) and epilepsy, exhibit sleep and circadian disturbances and seizure-like events. This study examines how chronic dim light at night (DLaN) exposure affects sleep architecture, EEG power spectra, and seizure activity in Cntnap2 KO and wildtype (WT) mice. Using electroencephalography (EEG) recordings, male and female Cntnap2 KO and WT mice were exposed to DLaN (5 lux) for 2 or 6 weeks. EEG recordings were analyzed to assess sleep architecture, power spectrum, and seizure-like events. DLaN exposure delays the wake onset and disrupts sleep patterns in a sex-dependent manner, with females being more affected. DLaN significantly increased slow-wave activity (SWA, 0.5–4 Hz) in both WT and KO mice, indicating increased sleep pressure. Finally, we found that DLaN dramatically increased the frequency of seizure-like events in the Cntnap2 KO mice and even increased the occurrence rate in the WT mice. Spectral analysis of seizure-like events revealed increased theta power, suggesting the involvement of hippocampus. Chronic DLaN exposure disrupts sleep and increases seizure-like events in Cntnap2 KO mice, with sex-specific differences. These findings emphasize the potential risks of nighttime light exposure for individuals with ASD and epilepsy, reinforcing the need to manage light exposure to improve sleep quality and reduce seizure risk.
- 17 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (1) , 150-157
Inhibitors of soluble epoxide hydrolase and cGAS/STING repair defects in amyloid-β clearance underlying vascular complications of Alzheimer's disease
Background: Alzheimer's disease (AD) and its monoclonal antibody therapies are associated with brain vasculitis and amyloid-related imaging abnormalities. The naturally-formed epoxides (EpFAs) of polyunsaturated fatty acids (PUFAs), such as 11,12-epoxyeicosatetraenoic acid (EEQ), are anti-inflammatory and pro-resolution mediators, which are increased by dietary supplementation with ω-3 PUFAs. EpFAs are, however, enzymatically hydrolyzed by soluble epoxide hydrolase (sEH) in AD patients' macrophages in vivo and in vitro . Objective: To repair amyloid-β 1-42 (Aβ) degradation by AD macrophages using the inhibitors of a) soluble epoxide hydrolase (sEHIs), termed TPPU and EC5026, together with EpFAs, or b) STING pathway termed H-151. Methods: Immunobiology, immunochemistry, RNA sequencing, and confocal microscopy were used. Results: In AD brain (examined postmortem), monocyte/macrophages upload Aβ in plaques and transfer it without degradation into brain microvessels, suffer apoptotis, and release Aβ, inducing vasculitis. The EpFAs of epoxyeicosatetraenoic acid (EEQ), along with the inhibitors TPPU and H-151, decrease inflammatory cytokines and regulate macrophage unfolded protein response to endoplasmic reticulum stress. Treatment of AD macrophages by TPPU with EEQ or by STING inhibitor H-151 increased uploading of Aβ after 2 hours and increased degradation of Aβ after 24 hours. Conclusions: The sEHI inhibitor EC5026 and the STING inhibitor H-151 increased macrophage uptake and degradation of Aβ. EC5026 administration was safe in normal volunteers. EC5026 together with ω-3 PUFA supplementation are indicated for in a clinical trial in patients with mild cognitive impairment.
- 17 February 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (1) , 150-157
Inhibitors of soluble epoxide hydrolase and cGAS/STING repair defects in amyloid-β clearance underlying vascular complications of Alzheimer's disease
Background: Alzheimer's disease (AD) and its monoclonal antibody therapies are associated with brain vasculitis and amyloid-related imaging abnormalities. The naturally-formed epoxides (EpFAs) of polyunsaturated fatty acids (PUFAs), such as 11,12-epoxyeicosatetraenoic acid (EEQ), are anti-inflammatory and pro-resolution mediators, which are increased by dietary supplementation with ω-3 PUFAs. EpFAs are, however, enzymatically hydrolyzed by soluble epoxide hydrolase (sEH) in AD patients' macrophages in vivo and in vitro . Objective: To repair amyloid-β 1-42 (Aβ) degradation by AD macrophages using the inhibitors of a) soluble epoxide hydrolase (sEHIs), termed TPPU and EC5026, together with EpFAs, or b) STING pathway termed H-151. Methods: Immunobiology, immunochemistry, RNA sequencing, and confocal microscopy were used. Results: In AD brain (examined postmortem), monocyte/macrophages upload Aβ in plaques and transfer it without degradation into brain microvessels, suffer apoptotis, and release Aβ, inducing vasculitis. The EpFAs of epoxyeicosatetraenoic acid (EEQ), along with the inhibitors TPPU and H-151, decrease inflammatory cytokines and regulate macrophage unfolded protein response to endoplasmic reticulum stress. Treatment of AD macrophages by TPPU with EEQ or by STING inhibitor H-151 increased uploading of Aβ after 2 hours and increased degradation of Aβ after 24 hours. Conclusions: The sEHI inhibitor EC5026 and the STING inhibitor H-151 increased macrophage uptake and degradation of Aβ. EC5026 administration was safe in normal volunteers. EC5026 together with ω-3 PUFA supplementation are indicated for in a clinical trial in patients with mild cognitive impairment.
- Open Access
- 31 October 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1478820
Reproductive hormones and sex chromosomes drive sex differences in the sleep–wake cycle
There are well-documented gender differences in the risk and severity of sleep disorders and associated comorbidities. While fundamental sex differences in sleep regulatory mechanisms may contribute to gender disparities, biological responses to sleep loss and stress may underlie many of the risks for sleep disorders in women and men. Some of these sex differences appear to be dependent on sex chromosome complement (XX or XY) and the organizational effects of reproductive hormones. Reproductive development plays a critical role in the ability of sex chromosomes and reproductive hormones to produce sex differences in sleep and wakefulness. Rodent models reveal that reproductive hormones drive many but not all sex differences in sleep–wake architecture. The ability of reproductive hormones to alter sleep are often dependent on responses to sleep loss and stress. However, in the absence of reproductive hormones (in gonadectomized rodents) sex differences in sleep amount and the ability to recover from sleep loss persist. The suprachiasmatic nucleus (SCN) and the ventrolateral preoptic nucleus (VLPO) of the hypothalamus play crucial regulatory roles in mediating the effects of reproductive hormones on the sleep–wake cycle. Taken together, the work reviewed here reveals that the reproductive hormone environment and sex chromosome complement may underlie gender disparities in sleep patterns and the risk for sleep disorders.
- 31 October 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1478820
Open AccessReproductive hormones and sex chromosomes drive sex differences in the sleep–wake cycle
There are well-documented gender differences in the risk and severity of sleep disorders and associated comorbidities. While fundamental sex differences in sleep regulatory mechanisms may contribute to gender disparities, biological responses to sleep loss and stress may underlie many of the risks for sleep disorders in women and men. Some of these sex differences appear to be dependent on sex chromosome complement (XX or XY) and the organizational effects of reproductive hormones. Reproductive development plays a critical role in the ability of sex chromosomes and reproductive hormones to produce sex differences in sleep and wakefulness. Rodent models reveal that reproductive hormones drive many but not all sex differences in sleep–wake architecture. The ability of reproductive hormones to alter sleep are often dependent on responses to sleep loss and stress. However, in the absence of reproductive hormones (in gonadectomized rodents) sex differences in sleep amount and the ability to recover from sleep loss persist. The suprachiasmatic nucleus (SCN) and the ventrolateral preoptic nucleus (VLPO) of the hypothalamus play crucial regulatory roles in mediating the effects of reproductive hormones on the sleep–wake cycle. Taken together, the work reviewed here reveals that the reproductive hormone environment and sex chromosome complement may underlie gender disparities in sleep patterns and the risk for sleep disorders.
- Open Access
- 5 August 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1427125
Scheduled feeding improves sleep in a mouse model of Huntington’s disease
Sleep disturbances are common features of neurodegenerative disorders including Huntington’s disease (HD). Sleep and circadian disruptions are recapitulated in animal models, providing the opportunity to evaluate the effectiveness of circadian interventions as countermeasures for neurodegenerative disease. For instance, time restricted feeding (TRF) successfully improved activity rhythms, sleep behavior and motor performance in mouse models of HD. Seeking to determine if these benefits extend to physiological measures of sleep, electroencephalography (EEG) was used to measure sleep/wake states and polysomnographic patterns in male and female wild-type (WT) and bacterial artificial chromosome transgenic (BACHD) adult mice, under TRF and ad lib feeding (ALF). Our findings show that male, but not female, BACHD mice exhibited significant changes in the temporal patterning of wake and non-rapid eye movement (NREM) sleep. The TRF intervention reduced the inappropriate early morning activity by increasing NREM sleep in the male BACHD mice. In addition, the scheduled feeding reduced sleep fragmentation (# bouts) in the male BACHD mice. The phase of the rhythm in rapid-eye movement (REM) sleep was significantly altered by the scheduled feeding in a sex-dependent manner. The treatment did impact the power spectral curves during the day in male but not female mice regardless of the genotype. Sleep homeostasis, as measured by the response to six hours of gentle handling, was not altered by the diet. Thus, TRF improves the temporal patterning and fragmentation of NREM sleep without impacting sleep homeostasis. This work adds critical support to the view that sleep is a modifiable risk factor in neurodegenerative diseases.
- 5 August 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1427125
Open AccessScheduled feeding improves sleep in a mouse model of Huntington’s disease
Sleep disturbances are common features of neurodegenerative disorders including Huntington’s disease (HD). Sleep and circadian disruptions are recapitulated in animal models, providing the opportunity to evaluate the effectiveness of circadian interventions as countermeasures for neurodegenerative disease. For instance, time restricted feeding (TRF) successfully improved activity rhythms, sleep behavior and motor performance in mouse models of HD. Seeking to determine if these benefits extend to physiological measures of sleep, electroencephalography (EEG) was used to measure sleep/wake states and polysomnographic patterns in male and female wild-type (WT) and bacterial artificial chromosome transgenic (BACHD) adult mice, under TRF and ad lib feeding (ALF). Our findings show that male, but not female, BACHD mice exhibited significant changes in the temporal patterning of wake and non-rapid eye movement (NREM) sleep. The TRF intervention reduced the inappropriate early morning activity by increasing NREM sleep in the male BACHD mice. In addition, the scheduled feeding reduced sleep fragmentation (# bouts) in the male BACHD mice. The phase of the rhythm in rapid-eye movement (REM) sleep was significantly altered by the scheduled feeding in a sex-dependent manner. The treatment did impact the power spectral curves during the day in male but not female mice regardless of the genotype. Sleep homeostasis, as measured by the response to six hours of gentle handling, was not altered by the diet. Thus, TRF improves the temporal patterning and fragmentation of NREM sleep without impacting sleep homeostasis. This work adds critical support to the view that sleep is a modifiable risk factor in neurodegenerative diseases.
- Open Access
Scheduled feeding improves sleep in a mouse model of Huntington’s disease
Sleep disturbances are common features of neurodegenerative disorders including Huntington’s disease (HD). The sleep and circadian disruptions are recapitulated in animal models, and these models provide the opportunity to evaluate whether circadian interventions can be effective countermeasures for neurodegenerative disease. Time restricted feeding (TRF) interventions successfully improve activity rhythms, sleep behavior and motor performance in mouse models of HD. Seeking to determine if these benefits of scheduled feeding extend to physiological measures of sleep, electroencephalography (EEG) was used to measure sleep/wake states and polysomnographic patterns in adult mice (six mo-old) under TRF and ad lib feeding (ALF). With each diet, both male and female wild-type (WT) and bacterial artificial chromosome transgenic (BACHD) mice were evaluated. Our findings show that male, but not female, BACHD mice exhibited significant changes in the temporal patterning of wake and non-rapid eye movement (NREM) sleep. The TRF intervention reduced the inappropriate early morning activity by increasing NREM sleep in the male BACHD mice. In addition, the scheduled feeding reduced sleep fragmentation (# bouts) in the male BACHD mice. The phase of the rhythm in rapid-eye movement (REM) sleep was significantly altered by the scheduled feeding. The treatment did impact the power spectral curves during the day in male but not female mice. Sleep homeostasis, as measured by the response to six hours of gentle handling, was not altered by the diet. Thus, TRF improves the temporal patterning and fragmentation of NREM sleep without impacting sleep homeostasis. This work adds critical support to the view that sleep is a modifiable risk factor in neurodegenerative diseases.
Open AccessScheduled feeding improves sleep in a mouse model of Huntington’s disease
Sleep disturbances are common features of neurodegenerative disorders including Huntington’s disease (HD). The sleep and circadian disruptions are recapitulated in animal models, and these models provide the opportunity to evaluate whether circadian interventions can be effective countermeasures for neurodegenerative disease. Time restricted feeding (TRF) interventions successfully improve activity rhythms, sleep behavior and motor performance in mouse models of HD. Seeking to determine if these benefits of scheduled feeding extend to physiological measures of sleep, electroencephalography (EEG) was used to measure sleep/wake states and polysomnographic patterns in adult mice (six mo-old) under TRF and ad lib feeding (ALF). With each diet, both male and female wild-type (WT) and bacterial artificial chromosome transgenic (BACHD) mice were evaluated. Our findings show that male, but not female, BACHD mice exhibited significant changes in the temporal patterning of wake and non-rapid eye movement (NREM) sleep. The TRF intervention reduced the inappropriate early morning activity by increasing NREM sleep in the male BACHD mice. In addition, the scheduled feeding reduced sleep fragmentation (# bouts) in the male BACHD mice. The phase of the rhythm in rapid-eye movement (REM) sleep was significantly altered by the scheduled feeding. The treatment did impact the power spectral curves during the day in male but not female mice. Sleep homeostasis, as measured by the response to six hours of gentle handling, was not altered by the diet. Thus, TRF improves the temporal patterning and fragmentation of NREM sleep without impacting sleep homeostasis. This work adds critical support to the view that sleep is a modifiable risk factor in neurodegenerative diseases.
- 16 April 2024
- Published by Springer Nature
- Vol. 2782, 123-136
Analysis of Human Peripheral Blood Mononuclear Cells in Patients with Neurodegenerative Diseases
The role of immune system in the progression of neurodegenerative diseases has been studied for decades in animal models. However, invasive studies in human subjects remain controversial due to the heterogeneity of the presentation of different diagnostic categories at different stages of the disease. Peripheral blood mononuclear cells (PBMCs) contain immune cells including dendritic cells (DCs), monocytes, macrophages, and T lymphocytes. Isolating PBMCs from whole blood samples collected from patients provides a minimally invasive method for analyzing the immune system’s function in patients with neurodegenerative diseases. By isolating single cell types from patients’ peripheral blood, in vitro analyses can be conducted including RNA sequencing, immunofluorescence, and phagocytic analysis. In this chapter, we discuss PBMC separation and isolation of macrophages in pure culture in vitro. We also outline methods for performing RNA-seq on cultured macrophages and other techniques for investigating the role of macrophages in neurodegenerative disease pathophysiology.
- 16 April 2024
- Published by Springer Nature
- Vol. 2782, 123-136
Analysis of Human Peripheral Blood Mononuclear Cells in Patients with Neurodegenerative Diseases
The role of immune system in the progression of neurodegenerative diseases has been studied for decades in animal models. However, invasive studies in human subjects remain controversial due to the heterogeneity of the presentation of different diagnostic categories at different stages of the disease. Peripheral blood mononuclear cells (PBMCs) contain immune cells including dendritic cells (DCs), monocytes, macrophages, and T lymphocytes. Isolating PBMCs from whole blood samples collected from patients provides a minimally invasive method for analyzing the immune system’s function in patients with neurodegenerative diseases. By isolating single cell types from patients’ peripheral blood, in vitro analyses can be conducted including RNA sequencing, immunofluorescence, and phagocytic analysis. In this chapter, we discuss PBMC separation and isolation of macrophages in pure culture in vitro. We also outline methods for performing RNA-seq on cultured macrophages and other techniques for investigating the role of macrophages in neurodegenerative disease pathophysiology.